Literature DB >> 26362756

Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis.

Elise Gaudin1, Laurence Seidel2, Miljana Bacevic3,4, Eric Rompen1, France Lambert1,3.   

Abstract

AIMS: The primary objective was to assess the occurrence rate of Medication-Related OsteoNecrosis of the Jaw (MRONJ) after dental extraction in patients treated with Antiresorptive Drugs (ARD) for OsteoPorosis (OP) or for oncological reasons. The secondary objective was to compare the extraction techniques regarding the occurrence of MRONJ.
MATERIALS AND METHODS: A systematic search in PubMed/MEDLINE, EMBASE and LILACS databases was performed. Prospective studies considering human patients treated with ARD and providing information regarding the occurrence of MRONJ after dental extraction were selected. Meta-analysis for incidence of MRONJ at the patient level was performed. The effect of administration route and surgical technique on MRONJ was evaluated.
RESULTS: The risk of MRONJ after dental extraction was significantly higher in patients treated with ARD for oncological reasons (3.2%) than in those treated with per os ARD for OP (0.15%) (p < 0.0001). Dental extraction performed with adjusted extraction protocols decreased significantly MRONJ development. Potential risk indicators such as concomitant medications and pre-existing osteomyelitis were identified.
CONCLUSION: The risk of MRONJ after dental extraction in patients treated with ARD exists, especially in patients treated for oncologic reasons. This risk tends to decrease with adjusted extraction protocols.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antiresorptive drug; bisphosphonates; dental extraction; meta-analysis; osteonecrosis of the jaw; systematic review

Mesh:

Substances:

Year:  2015        PMID: 26362756     DOI: 10.1111/jcpe.12455

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  21 in total

1.  Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Authors:  T Hasegawa; S Hayashida; E Kondo; Y Takeda; H Miyamoto; Y Kawaoka; N Ueda; E Iwata; H Nakahara; M Kobayashi; S Soutome; S I Yamada; I Tojyo; Y Kojima; M Umeda; S Fujita; H Kurita; Y Shibuya; T Kirita; T Komori
Journal:  Osteoporos Int       Date:  2018-11-07       Impact factor: 4.507

2.  Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Authors:  Valesca S Koth; Maria A Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2017-02-17       Impact factor: 2.419

Review 3.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

4.  A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Authors:  T Hasegawa; A Kawakita; N Ueda; R Funahara; A Tachibana; M Kobayashi; E Kondou; D Takeda; Y Kojima; S Sato; S Yanamoto; H Komatsubara; M Umeda; T Kirita; H Kurita; Y Shibuya; T Komori
Journal:  Osteoporos Int       Date:  2017-04-27       Impact factor: 4.507

5.  The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study.

Authors:  Yi-Fang Huang; Chih-Hsin Muo; Chun-Hao Tsai; Shih-Ping Liu; Chung-Ta Chang
Journal:  Clin Oral Investig       Date:  2018-05-03       Impact factor: 3.573

Review 6.  Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.

Authors:  L Dos Santos Ferreira; L G Abreu; C B Calderipe; M D Martins; L F Schuch; A C U Vasconcelos
Journal:  Osteoporos Int       Date:  2021-07-31       Impact factor: 4.507

7.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

8.  Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis.

Authors:  Ruri Komiya; Takahiro Wada; Fumihiko Tsushima; Kei Sakamoto; Tohru Ikeda; Akira Yamaguchi; Hiroyuki Harada; Motohiro Uo
Journal:  J Bone Miner Metab       Date:  2018-11-22       Impact factor: 2.626

9.  Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know.

Authors:  Emanuel Bruckmoser; Miriam Palaoro; Lukas Latzko; Dagmar Schnabl; Sabrina B Neururer; Johannes Laimer
Journal:  Int J Environ Res Public Health       Date:  2021-04-22       Impact factor: 3.390

10.  The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Michele Miranda; Francesco Gianfreda; Carlo Raffone; Donato Antonacci; Valeria Pistilli; Patrizio Bollero
Journal:  Biomed Res Int       Date:  2021-05-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.